News – Page 922 – Endpoints News

Ex-DARPA director pursues all-in-one cancer pill as NED CEO; Karyopharm loses commercial chief ahead of drug rollout

6 years ago

ICER update on Duchenne drugs pushes up price estimates for Exondys 51, Emflaza ahead of July panel review

6 years ago

Supercharging CAR-T with cancer vaccine, MIT team spotlights some new tech underpinning Darrell Irvine's startup

6 years ago

Broad star Feng Zhang unveils a new CRISPR platform, editing RNA and eliminating Alzheimer's threat — in cells

6 years ago

FDA revises 1999 draft guidance on population pharmacokinetics

6 years ago

Amgen, Novartis scrap Alzheimer's studies — is BACE finally dead or will Biogen and Eisai carry on?

6 years ago

Fresh out of Eli Lilly, Christi Shaw surfaces as Daniel O'Day's new CEO at CAR-T pioneer Kite

6 years ago

Eli Lilly's Christi Shaw bows out of top post at the Bio-Medicines unit

6 years ago

No clear answers: Yes, recent actions against Chinese American scientists do pose a threat — but maybe those ...

6 years ago

Alnylam’s Maraganore switches ‘perhaps the best CFO in mid-cap biotech’ with Shire vet Jeff Poulton

6 years ago

After a radical downsizing, Teva beefs up US R&D campus; Tiaki recruits Suzanne Bruhn for the helm

6 years ago

Scripps-led consortium scores $129M NIH grant to work on vaccine for stubborn HIV

6 years ago

Faced with a PhIII flop in NASH, Gilead is sequencing 15,000 patients to find new drugs

6 years ago

Analysis: In most of the Big Pharma world, R&D spending towers over revenue from new drugs. Guess who beat the odds

6 years ago

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

6 years ago

White House changes course to kill rebate reform

6 years ago

Can a Medicare Advantage insurer be great at drug development for their target audience?

6 years ago

GlaxoSmithKline recruits a new coach and top player for their AI/ML team out of Genentech and MIT

6 years ago

Astex vet Neil Thompson looks to build discovery from scratch at rare disease AI upstart out of Cambridge, UK

6 years ago

Sanofi begins countdown for FDA isatuximab review; Cirrhosis-focused biotech presents another mini IPO

6 years ago

Genmab steps up for a $500M IPO haul, with its sights on a record-setting market cap

6 years ago

Supply constraints push EpiPen rival maker Amneal to restructure, shares fall

6 years ago

The FDA's Janet Woodcock talks about some big changes she's pushing for in drug development, and agency reviews

6 years ago

Fresh out of beleaguered Merrimack, Richard Peters jumps into the welcome arms of Tony Coles at Yumanity

6 years ago

First page Previous page 919 920 921922923 924 925 Next page Last page